Management of Intestinal Complications in Patients With Pelvic Radiation Disease

被引:36
作者
Fuccio, Lorenzo [1 ]
Guido, Alessandra [2 ]
Andreyev, H. Jervoise N. [3 ]
机构
[1] Univ Bologna, S Orsola M Malpighi Hosp, Dept Clin Med, I-40136 Bologna, Italy
[2] St Orsola Marcello Malpighi Hosp, Div Radiat Oncol, Bologna, Italy
[3] Royal Marsden Hosp, Gastrointestinal Unit, London SW3 6JJ, England
基金
美国国家卫生研究院;
关键词
Side Effect; Tumor; Irradiate; Mucosa; Tissue Damage; ARGON PLASMA COAGULATION; HYPERBARIC-OXYGEN TREATMENT; INTENSITY-MODULATED RADIOTHERAPY; MISOPROSTOL RECTAL SUPPOSITORIES; INDUCED HEMORRHAGIC PROCTITIS; PLACEBO-CONTROLLED TRIAL; PROSTATE-CANCER PATIENTS; CHAIN FATTY-ACIDS; DOUBLE-BLIND; GASTROINTESTINAL SYMPTOMS;
D O I
10.1016/j.cgh.2012.07.017
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Gastrointestinal toxicity after radiotherapy for pelvic cancer is a major complication-the most commonly reported symptoms include rectal bleeding, diarrhea, and fecal incontinence, which substantially impair patients' quality of life. Management of these symptoms can be a challenge, although available treatment strategies generally are ignored or underused. Radiation-induced symptoms have multiple mechanisms of pathogenesis; the first step for the correct management is to identify the mechanism that is causing the symptoms. Optimal management requires close liaisons among physicians, gastroenterologists with specialist interests, radiotherapists, oncologists, dieticians, nurses, and surgeons. Patients should be reassured that treatment options (medical, endoscopic, and surgical) exist and are in most cases successful if patients are referred to experts in pelvic radiation disease. However, although new therapeutic approaches are not yet always supported by high-quality trials, research projects are underway to improve management of patients. Clinicians should focus on using proven treatments correctly and avoiding misuse.
引用
收藏
页码:1326 / +
页数:13
相关论文
共 93 条
[1]   Gastrointestinal problems after pelvic radiotherapy: the past, the present and the future [J].
Andreyev, H. J. N. .
CLINICAL ONCOLOGY, 2007, 19 (10) :790-799
[2]   Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer [J].
Andreyev, H. Jervoise N. ;
Davidson, Susan E. ;
Gillespie, Catherine ;
Allum, William H. ;
Swarbrick, Edwin .
GUT, 2012, 61 (02) :179-192
[3]   Defining pelvic-radiation disease for the survivorship era [J].
Andreyev, H. Jervoise N. ;
Wotherspoon, Andrew ;
Denham, James W. ;
Hauer-Jensen, Martin .
LANCET ONCOLOGY, 2010, 11 (04) :310-312
[4]   Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients [J].
Andreyev, Jervoise .
LANCET ONCOLOGY, 2007, 8 (11) :1007-1017
[5]  
[Anonymous], CA CANC J CLIN, DOI DOI 10.3322/CAAC.20107
[6]  
[Anonymous], SMALL BOWEL COLON
[7]   Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: Results of a randomized trial [J].
Athanassiou, H ;
Antonadou, D ;
Coliarakis, N ;
Kouveli, A ;
Synodinou, M ;
Paraskevaidis, M ;
Sarris, G ;
Georgakopoulos, GR ;
Panousaki, K ;
Karageorgis, P ;
Throuvalas, N .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (04) :1154-1160
[8]   The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients [J].
Bacon, CG ;
Giovannucci, E ;
Testa, M ;
Glass, TA ;
Kawachi, I .
CANCER, 2002, 94 (03) :862-871
[9]   Topical phenylephrine in the treatment of radiation-induced faecal incontinence [J].
Badvie, S ;
Andreyev, HJN .
CLINICAL ONCOLOGY, 2005, 17 (02) :122-126
[10]   The Impact of Clinical Factors on the Development of Late Radiation Toxicity: Results from the Medical Research Council RT01 Trial (ISRCTN47772397) [J].
Barnett, G. C. ;
De Meerleer, G. ;
Gulliford, S. L. ;
Sydes, M. R. ;
Elliott, R. M. ;
Dearnaley, D. P. .
CLINICAL ONCOLOGY, 2011, 23 (09) :613-624